VEA
TCRR

Virtus ETF Advisers’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Virtus ETF Advisers’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-11,762
Closed -$100K – 410
2021
Q3 		$100K Sell
11,762
-617
-5% -$8.72K 0.04% 382
2021
Q2 		$203K Buy
12,379
+1,696
+16% +$34.3K 0.08% 337
2021
Q1 		$236K Buy
10,683
+192
+2% +$5.24K 0.1% 302
2020
Q4 		$324K Buy
+10,491
New +$265K 0.13% 191

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Virtus ETF Advisers's TCRR Position: Q4 2021 in Review

Virtus ETF Advisers sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q4 2021, closing a stake of 11,762 shares — an estimated $100K sold.

Virtus ETF Advisers first reported a position in TCRR in Q4 2020 and held it in 4 quarters. The position peaked at $324K in Q4 2020. 122 funds tracked by Wall St. Rank hold TCRR as of Q4 2021.

  • Virtus ETF Advisers reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Virtus ETF Advisers sold 11,762 TCR2 Therapeutics Inc. Common Stock shares in Q4 2021, an estimated $100K.
  • Virtus ETF Advisers first reported a position in TCR2 Therapeutics Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Virtus ETF Advisers's TCR2 Therapeutics Inc. Common Stock position peaked at $324K in Q4 2020.
  • 122 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q4 2021.

Based on Virtus ETF Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.